Search

Your search keyword '"Joven, B."' showing total 133 results
Start Over Author "Joven, B."
133 results on '"Joven, B."'

3. A Causal-Mentalist View of Propositions

Author

Jeremiah Joven B. Joaquin and James Franklin

Subjects
propositions, causal-mentalist view, cluster analysis, game theory, perception algorithms, platonism, symbol grounding, Philosophy (General), B1-5802
Abstract

In order to fulfil their essential roles as the bearers of truth and the relata of logical relations, propositions must be public and shareable. That requirement has favoured Platonist and other non-mental views of them, despite the well-known problems of Platonism in general. Views that propositions are mental entities have correspondingly fallen out of favour, as they have difficulty in explaining how propositions could have shareable, objective properties. We revive a mentalist view of propositions, inspired by Artificial Intelligence work on perceptual algorithms, which shows how perception causes persistent mental entities with shareable properties that allow them to fulfil the traditional roles of (one core kind of) propositions. The clustering algorithms implemented in perception produce outputs which are (implicit) atomic propositions in different minds. Coordination of them across minds proceeds by game-theoretic processes of communication. The account does not rely on any unexplained notions such as mental content, representation, or correspondence (although those notions are applicable in philosophical analysis of the result).

Published
2022
Full Text
View/download PDF

4. Position statement for the management of comorbidities in psoriasis

Author

Dauden, E., Blasco, A.J., Bonanad, C., Botella, R., Carrascosa, J.M., González Parra, E., Jodar, E., Joven, B., Lázaro, P., Olveira, A., Quintero Gutiérrez Del Álamo, Francisco Javier, Rivera, R., Dauden, E., Blasco, A.J., Bonanad, C., Botella, R., Carrascosa, J.M., González Parra, E., Jodar, E., Joven, B., Lázaro, P., Olveira, A., Quintero Gutiérrez Del Álamo, Francisco Javier, and Rivera, R.

Abstract

Background The association between psoriasis and some diseases has become relevant in recent years. Providing appropriate management of psoriasis from an early stage requires prompt diagnosis and treatment of concomitant dis- eases and to prevent any potential comorbidity. This approach should consider the adverse events of the drugs used to treat psoriasis potentially related to the onset of comorbidities. Objective To provide the dermatologist with an accurate and friendly tool for systematizing the diagnosis of psoriasis- associated comorbidities, which generally escapes the scope of the dermatology setting, and to facilitate decision-mak- ing about the referral and treatment of patients with comorbidities. Methods These position statement recommendations were developed by a working group composed of ten experts (four dermatologists, one cardiologist, one rheumatologist, one gastroenterologist, one nephrologist, one endocrinologist and one psychiatrist) and two health services researchers. The expert group selected the psoriasis comorbidities considered according to their relevance in the dermatology setting. The recommendations on diagnostic criteria are based on the cur- rent clinical practice guidelines for each of the comorbidities. The information regarding the repercussion of psoriasis medi- cal treatments on associated comorbid diseases was obtained from the summary of product characteristics of each drug. Results Recommendations were developed to detect and refer the following psoriasis comorbidities: psoriatic arthritis, cardiovascular risk factors (diabetes, dyslipidaemia, obesity, hypertension and metabolic syndrome), non-alcoholic fatty liver disease, inflammatory bowel disease, kidney disease and psychological disorders (anxiety and depression). In addi- tion, alcohol consumption and tobacco consumption were included. The tables and figures are precise, easy-to-use tools to systematize the diagnosis of comorbidities in patients with psoriasis and fac, Fundación Investigación Clinico-Dermatológica, Instituto de Salud Carlos III, Depto. de Medicina Legal, Psiquiatría y Patología, Fac. de Medicina, TRUE, pub

Published
2024

6. The Philippine Higher Education Sector in the Time of COVID-19

Author

Jeremiah Joven B. Joaquin, Hazel T. Biana, and Mark Anthony Dacela

Subjects
COVID-19, Philippine education, policy and institutional actions, online learning, distance education, flexible learning, Education (General), L7-991
Abstract

This paper reports the policy-responses of different Philippine higher education institutions (HEIs) to the novel coronavirus, COVD-19 pandemic. It compares these responses with those made by HEIs in Indonesia, Thailand, and Vietnam. Publicly available data and news reports were used to gauge the general public’s reaction to these policies and how the Philippines’ responses fare with its Southeast Asian neighbors. The paper observes that despite the innovations made by Philippine HEIs in terms of alternative learning modes and technologies for delivering education, there are still gaps and challenges in their responses. It recommends that policy-responses and learning innovations should be grounded on a deeper understanding of distance education and should be sensitive to the call of the times.

Published
2020
Full Text
View/download PDF

9. THE MEANING OF LOGICAL CONNECTIVES AND PRIOR'S TONK ARGUMENT.

Author

Joaquin, Jeremiah Joven B.

Subjects
ARGUMENT, PHILOSOPHERS
Abstract

In "The Runabout Inference-Ticket," the New Zealand-born philosopher and logician Arthur N. Prior presented the tonk argument as a case against the inferential role view of logical connectives -- the view that the meaning of a given logical connective is completely determined by its roles in deductively valid arguments. This paper evaluates the salient literature surrounding Prior's argument to draw some insights into what precisely it is supposed to show. In particular, it argues that combined with Prior's later thoughts expressed in "Conjunction and contonktion revisited," the tonk argument suggests a more metaphysical-cum-epistemic rather than just a purely (meta) logical view of the nature of logical connectives. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. From Social Construction to Social Critique: An Interview with Sally Haslanger

Author

Jeremiah Joven B. Joaquin and Hazel T. Biana

Subjects
Gender Studies, Philosophy
Abstract

Sally Haslanger (b. 1955) is Ford Professor of Philosophy and Women's and Gender Studies at the Massachusetts Institute of Technology and a leading contemporary feminist philosopher. She has worked on analytic metaphysics, epistemology, and ancient philosophy. Her areas of interest are social and political philosophy, feminist theory, and critical race theory. Her 2012 book, Resisting Reality: Social Construction and Social Critique, collects papers published over the course of twenty years that link work in contemporary metaphysics, epistemology, and philosophy of language with social and political issues concerning gender, race, and the family. It was awarded the 2014 Joseph B. Gittler Prize for “outstanding scholarly contribution in the field of the philosophy of one or more of the social sciences.” In this interview, done in the wake of the COVID-19 pandemic and the #BlackLivesMatter movement, we discuss her ideas on social practices, social structure, and structural explanation. We also delve into her debunking project of elucidating the notion of ideology in a way that links it with contemporary work in epistemology, philosophy of language, and philosophy of mind, and to do justice to the materiality of social practices and social structures.

Published
2022

11. LOVE BYTES: THE FUTURE OF BIO–R2 RELATIONSHIPS

Author

Jeremiah Joven B. Joaquin and Hazel T. Biana

Subjects
General Medicine
Abstract

What would a romantic relationship between a biological human and an artificial intelligence system look like? The question is explored through a fictional correspondence between Alan Turing and Ada Lovelace.

Published
2022

12. CO22 Use of Ixekizumab for Psoriatic Arthritis Patients in Real-World Conditions

Author

Joven, B, primary, Hernández Sánchez, R, additional, Pérez Pampín, E, additional, Aragón Díez, Á, additional, Almodovar, R, additional, Martínez-Ferrer, A, additional, Belzunegui, J, additional, Rubio, E, additional, Díaz Cerezo, S, additional, Moyano, S, additional, Trancho, L, additional, Gómez Barrera, M, additional, Muñoz, Á, additional, and Nuñez, M, additional

Published
2022
Full Text
View/download PDF

14. Late Skin Fibrosis in Systemic Sclerosis: A Study from the EUSTAR Cohort

Author

Michael Hughes 1 2, Suiyuan Huang 3 4, Juan Jose Alegre-Sancho 5, Patricia E Carreira 6, Merete Engelhart 7, Eric Hachulla 8, Joerg Henes 9, Eduardo Kerzberg 10, Maria Rosa Pozzi 11, Gabriela Riemekasten 12, Vanessa Smith 13, Gabriella Szücs 14, Marie Vanthuyne 15, Elisabetta Zanatta 16, Oliver Distler 17, Armando G Gabrielli 18, Anna-Maria Hoffmann-Vold 19, Virginia D Steen 20, Dinesh Khanna 3 21, EUSTAR Airò P, Allanore A, Ananieva Lp, Anic B, Balbir-Gurman A, Becvar R, Benvenuti F, Cantatore F P, Chung L S, Cuomo G, Cutolo M, Czirják L, Damjanov N, de Vries-Bouwstra J, Del Galdo F, Distler J, Eyerich K, Farge D, Foti R, Gheorghiu A M, Giollo A, Heitmann S, Herrick A, Hesselstrand R, Hsu I M, Hunzelmann N, Iannone F, Iudici M, Ionescuc M R, Ingegnoli F, Jose J, Joven B E, Kerzberg E, Kucharz E J, Kuwana M, Langhe E D, Launay D, Lefebvre P, Litinsky I, García de la Peña Lefebvre P, González-Martín J J, Li M, Loyo E, Martin T, Matucci-Cerinic M, Maurer B, Moroncini G, Mouthon L, Müller Cs, Müller-Ladner U, Novak S, Pastor P, Pecher A-C, Pellerito R, Pozzi M R, Oksel F, Rednic S, Rezus E, Riccieri V, Rosato E, Saketkoo L A, Salvador M J, Schmeiser T, Selmi C F, Sibilia J, Siegert E, Solanki K, Sommerlatte S, Spertini F, Stamenkovic B, Stamp L, Tanaseanu C-M, Tikly M, Tineo C, Ullman S, Üprus M, Vanthuyne M, Veale D, Walker U, Wiland P, Yargucu F, Yavuz S, University of Zurich, Michael Hughes, 1 2, Suiyuan Huang, 3 4, Juan Jose Alegre-Sancho, 5, Patricia, E Carreira 6, Merete Engelhart, 7, Eric Hachulla, 8, Joerg Henes, 9, Eduardo Kerzberg, 10, Maria Rosa Pozzi, 11, Gabriela Riemekasten, 12, Vanessa Smith, 13, Gabriella Szücs, 14, Marie Vanthuyne, 15, Elisabetta Zanatta, 16, Oliver Distler, 17, Armando, G Gabrielli 18, Anna-Maria Hoffmann-Vold, 19, Virginia, D Steen 20, Dinesh Khanna, 3 21, EUSTAR Airò, P, Allanore, A, Ananieva, Lp, Anic, B, Balbir-Gurman, A, Becvar, R, Benvenuti, F, Cantatore, F P, Chung, L S, Cuomo, G, Cutolo, M, Czirják, L, Damjanov, N, de Vries-Bouwstra, J, Del Galdo, F, Distler, J, Eyerich, K, Farge, D, Foti, R, Gheorghiu, A M, Giollo, A, Heitmann, S, Herrick, A, Hesselstrand, R, Hsu, I M, Hunzelmann, N, Iannone, F, Iudici, M, Ionescuc, M R, Ingegnoli, F, Jose, J, Joven, B E, Kerzberg, E, Kucharz, E J, Kuwana, M, Langhe, E D, Launay, D, Lefebvre, P, Litinsky, I, García de la Peña Lefebvre, P, González-Martín, J J, Li, M, Loyo, E, Martin, T, Matucci-Cerinic, M, Maurer, B, Moroncini, G, Mouthon, L, Müller, C, Müller-Ladner, U, Novak, S, Pastor, P, Pecher, A-C, Pellerito, R, Pozzi, M R, Oksel, F, Rednic, S, Rezus, E, Riccieri, V, Rosato, E, Saketkoo, L A, Salvador, M J, Schmeiser, T, Selmi, C F, Sibilia, J, Siegert, E, Solanki, K, Sommerlatte, S, Spertini, F, Stamenkovic, B, Stamp, L, Tanaseanu, C-M, Tikly, M, Tineo, C, Ullman, S, Üprus, M, Vanthuyne, M, Veale, D, Walker, U, Wiland, P, Yargucu, F, and Yavuz, S

Subjects
Rheumatology, Cohort enrichment, 10051 Rheumatology Clinic and Institute of Physical Medicine, Late disease, Systemic sclerosis, Pharmacology (medical), 610 Medicine & health, Fibrosis, Clinical trial design, Scleroderma, Skin
Abstract

Objectives The early trajectory of skin fibrosis provides insights into the disease course of systemic sclerosis (SSc) including mortality; however, little is known about late skin fibrosis. The aims of our study were to ascertain the prevalence and characteristics of late skin fibrosis in SSc. Methods We developed and tested three conceptual scenarios of late (>5 years after first non-RP feature) skin fibrosis including new worsening of skin disease, and failure to improve after worsening within 5-year window. We defined skin worsening as change in modified Rodnan skin score (mRSS) ≥5 units or ≥25%. Using strict inclusion criteria including complete mRSS, we identified 1,043 (out of 19 115) patients within the EUSTAR database for our analysis. We further restricted analysis within 887 (out of 1043) patients who had lcSSc or dcSSc at baseline. Results One-fifth of patients among the whole cohort (n = 208/1043, 19.9%) experienced mRSS worsening, including in patients with lcSSc or dcSSc at baseline (n = 193/887, 21.8%). This was largely due to new skin worsening after the 5-year window or failure to improve with worsening within the 5-year window. Patients with lower baseline mRSS and lcSSc were more likely to develop late skin fibrosis. Anti-Scl-70 was associated with progression from baseline lcSSc to dcSSc, and anticentromere was protective. Conclusions Late skin fibrosis is not uncommon in SSc. We have identified different patterns relevant to clinical practice and trial design. Late skin fibrosis is a neglected manifestation of SSc and warrants further investigation including to determine clinical outcomes and optimal therapeutic strategy.

Published
2022

15. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis

Author

Ferreiro-Iglesias, A, Montes, A, Perez-Pampin, E, Cañete, J D, Raya, E, Magro-Checa, C, Vasilopoulos, Y, Sarafidou, T, Caliz, R, Ferrer, M A, Joven, B, Carreira, P, Balsa, A, Pascual-Salcedo, D, Blanco, F J, Moreno-Ramos, M J, Fernández-Nebro, A, Ordóñez, M C, Alegre-Sancho, J J, Narváez, J, Navarro-Sarabia, F, Moreira, V, Valor, L, García-Portales, R, Marquez, A, Martin, J, Gómez-Reino, J J, and Gonzalez, A

Published
2016
Full Text
View/download PDF

18. QUESTIONING DEMETERIO'S APPROACH TO FILIPINO PHILOSOPHY.

Author

Biana, Hazel T. and Joaquin, Jeremiah Joven B.

Subjects
FILIPINOS, PHILOSOPHERS, EMPLOYMENT, DISCOURSE, BIBLIOMETRICS
Abstract

In his two articles, F. P. A. Demeterio III attempts to classify works in Filipino philosophy using a list of twelve (or sixteen) supposed discourses that prominent philosophers in the Philippines have engaged in and published over the past few years. From this list, he advises current Filipino philosophers to invest their time and effort in contributing to only five of these because of their alleged higher measure of "developmental potential" as opposed to other discourses. In this paper, we raise some fundamental issues with Demeterio's approach. We show that (i) his work's conclusions rest on questionable methodological assumptions that make (ii) the discourses which the work arrived at and the rankings in terms of "developmental potential" superficial and ungrounded. Finally, (iii) instead of fulfilling the main aim of advancing research in Filipino philosophy, the proposed approach may actually lead to its stagnation and demise. We argue that these issues, if left unanswered, make Demeterio's whole approach to Filipino philosophy unsound and may put into question the employment of such an approach. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

20. Lucius T. Outlaw, Jr. On why Racism makes No Sense.

Author

BIANA, Hazel T. and JOAQUIN, Jeremiah Joven B.

Subjects
RACISM, SOCIAL constructionism, BLACK people, EXPERIENCE, PHILOSOPHY, METAPHYSICS, CONSCIOUSNESS
Abstract

In this interview with W. Alton Jones Professor of Philosophy at Vanderbilt University, Lucius T. Outlaw, Jr, we discuss the metaphysical and ethical questions of grouping and classifying people in terms of race and ethnicity. Outlaw is the author of [On Race and Philosophy] and one of the recognised pioneers of Africana Philosophy. Outlaw talks about growing up in racial segregation in Starkville, Mississippi, the Black Power movement, the notion of the Black intellectual, scholarship and teaching, and philosophizing about race. We discuss the ambiguity of the concept of philosophy of race and explore the concepts of raciality, categories, human sociality, evolution, and oppression. With his philosophical, political, and sociological influences, Outlaw asserts that racism makes no sense at all because the diversity of our species is one of our greatest assets; and in terms of survival, we are all of the same species though certain group-shared differences do matter. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

22. Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice

Author

Galíndez-Agirregoikoa E, Prieto-Peña D, Martín-Varillas JL, Joven B, Rusinovich O, Melero-González RB, Ortiz-Sanjuan F, Almodóvar R, Alegre JJ, Martínez Á, Sellas-Fernández A, Méndez L, García-Vicuña R, Atienza-Mateo B, Gorostiza I, González-Gay MÁ, and Blanco R

Subjects
psoriatic arthritis, tofacitinib, real-world data, biologic therapy, clinical practice
Abstract

Objective. Tofacitinib (TOF) is the first Janus kinase (JAK) inhibitor approved for psoriatic arthritis (PsA). It has shown efficacy in patients refractory to anti-tumor necrosis factor-alpha in randomized controlled trials (RCTs). Our aim was to assess efficacy and safety of TOF in clinical practice. Methods. This was an observational, open-label multicenter study of PsA patients treated with TOF due to inefficacy or adverse events of previous therapies. Outcome variables were efficacy, corticosteroid dose-sparing effect, retention rate, and safety. A comparative study of clinical features between our cohort of patients and those from the OPAL Beyond trial was performed. Results. There were 87 patients (28 women/59 men), with a mean age of 52.8 +/- 11.4 years. All patients were refractory to biologic disease-modifying antirheumatic drugs (DMARDs) and/or to conventional synthetic DMARDs plus apremilast. TOF was started at 5 mg twice daily after a mean follow-up of 12.3 +/- 9.3 years from PsA diagnosis. At first month, Disease Activity Score in 28 joints based on erythrocyte sedimentation rate (DAS28-ESR) decreased from median 4.8 (IQR 4.1-5.4) to 3.7 (IQR 2.8-4.7, P < 0.01), Disease Activity Index for Psoriatic Arthritis from median 28 (IQR 18.4-34.1) to 15.5 (IQR 10.1-25.7, P < 0.01), and C-reactive protein from median 1.9 (IQR 0.3-5.0) to 0.5 (IQR 0.1-2.2) mg/dL (P < 0.01). Also, TOF led to a significant reduction in prednisone dose. Mild adverse effects were reported in 21 patients (24.13%), mainly gastrointestinal symptoms. TOF retention rate at Month 6 was 77% (95% CI 65.2-86.3). Patients in clinical practice were older with longer disease duration and received biologic agents more commonly than those in the OPAL Beyond trial. Conclusion. Data from clinical practice confirm that TOF seems to be effective, rapid, and relatively safe in refractory PsA despite clinical differences with patients in RCTs.

Published
2021

23. CLARO R. CENIZA ON CONDITIONALS, PROBABILITY, AND MODALITY.

Author

Joaquin, Jeremiah Joven B.

Subjects
MODAL logic, MODALITY (Linguistics), PROBABILITY theory, PHILOSOPHERS, METAPHYSICS
Abstract

Claro R. Ceniza [1927-2001] is arguably one of the best philosophers that the Philippines has ever produced. However, it is quite unfortunate that some of his important contributions are not that wellknown. This paper aims to rectify this by presenting an evaluation of his original insights on three outstanding problems in philosophy, viz., the paradoxes of material implication, the nature of probability, and the metaphysics of modality. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

24. COVID-19: The need to heed distress calls of healthcare workers

Author

Biana, Hazel T and Joaquin, Jeremiah Joven B

Subjects
2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), SARS-CoV-2, business.industry, Health Personnel, Philippines, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Public Health, Environmental and Occupational Health, MEDLINE, COVID-19, General Medicine, medicine.disease, Distress, Health care, Correspondence, Government Regulation, medicine, Humans, AcademicSubjects/MED00860, Medical emergency, business, Psychology, Pandemics
Published
2020

25. Arthur N. Prior on 'Unquestionably the Best Logical Symbolism for Most Purposes'.

Author

Joaquin, Jeremiah Joven B.

Subjects
*SYMBOLISM, *LOGICIANS, *MATHEMATICIANS, *MODAL logic
Abstract

In his Formal Logic, Arthur N. Prior (1914–1969) declared that Jan Łukasiewicz's logical notation is 'unquestionably the best logical symbolism for most purposes'. Whether he had a substantive, and not only practical, reason for this notational preference is unclear. Through an investigation of his philosophical outlook towards the nature of logic and representation in general, and the nature of logical 'operators' in particular, this paper suggests that there might be a substantive argument for this declaration. This argument is premised on Prior's own metaphysical view that an adequate notation must represent the functional nature of these operators. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

31. Genetic variation in the nuclear factor κB pathway in relation to susceptibility to rheumatoid arthritis

Author

Dieguez-Gonzalez, R, Akar, S, Calaza, M, Perez-Pampin, E, Costas, J, Torres, M, Vicario, J L, Velloso, M L, Navarro, F, Narvaez, J, Joven, B, Herrero-Beaumont, G, Gonzalez-Alvaro, I, Fernandez-Gutierrez, B, de la Serna, A R, Carreño, L, Lopez-Longo, J, Caliz, R, Collado-Escobar, M D, Blanco, F J, Fernandez-Lopez, C, Balsa, A, Pascual-Salcedo, D, Gomez-Reino, J J, and Gonzalez, A

Published
2009
Full Text
View/download PDF

33. Genetic variation in the nuclear factor (kappa)B pathway in relation to susceptibility to rheumatoid arthritis

Author

Dieguez-Gonzalez, R., Akar, S., Calaza, M., Perez-Pampin, E., Costas, J., Torres, M., Vicario, J.L., Velloso, M.L., Navarro, F., Narvaez, J., Joven, B., Herrero-Beaumont, G., Gonzalez-Alvaro, I., Fernandez-Gutierrez, B., de la Serna, A.R., Carreno, L., Lopez-Longo, J., Caliz, R., Collado-Escobar, M.D., Blanco, F.J., Fernandez-Lopez, C., Balsa, A., Pascual-Salcedo, D., Gomez-Reino, J.J., and Gonzalez, A.

Subjects
Rheumatoid arthritis -- Genetic aspects, Rheumatoid arthritis -- Risk factors, Rheumatoid arthritis -- Research, Genetic variation -- Research, Health
Published
2009

36. Philippine crimes of dissent: Free speech in the time of COVID-19.

Author

Joaquin, Jeremiah Joven B and Biana, Hazel T

Subjects
COVID-19, FREEDOM of speech, CRIME, COVID-19 pandemic, POSTFEMINISM, SARS-CoV-2
Abstract

The novel coronavirus disease, COVID-19, has become a global health crisis, where, as of June 13, 2020, hundreds of thousands have died and millions of people have been infected. In a country with a dual and decentralised healthcare system, wherein only a part of the health premiums are subsidised by the government, the pandemic is a huge health challenge because of resource and capacity limitations. Alarmed by the human rights abuses that the Anti-Terrorism law may bring, the International Coalition for Human Rights in the Philippines (ICHRP) Chairman Peter Murphy stated that the government seems to be 'giving priority to repressive legislation but remains bungling in addressing the pandemic. [Extracted from the article]

Published
2021
Full Text
View/download PDF

37. S.4.1 N-terminal pro-brain natriuretic peptide levels predict incident pulmonary arterial hypertension in SSc

Author

Thakkar, V., Stevens, W., Prior, D., Byron, J., Patterson, K., Hissaria, P., Moore, O., Roddy, J., Zochling, J., Sahhar, J., Nash, P., Tymms, K., Youssef, P., Proudman, S., Nikpour, M., Launay, D., Sitbon, O., Cordier, J. F., Hachulla, E., Mouthon, L., Gressin, V., Rottat, L., Clerson, P., Simonneau, G., Humbert, M., Carreira, P., Carmona, L., Joven, B. E., Denton, C. P., Allanore, Y., Walker, U. A., Matucci-Cerinic, M., Muller-Ladner, U., Hsu, V., Cheng, Q., and Steen, V.

Abstract

Introduction. Pulmonary arterial hypertension (PAH) is a major cause of mortality in SSc. NT-proBNP may be a useful biomarker of prevalent PAH but its role in screening for incident PAH has not been evaluated. Methods. Patients recruited into the Australian Scleroderma Cohort Study undergo annual echocardiography, pulmonary function tests (PFTs), 6-min walk test (6MWT) and have serum NT-proBNP measured (ElecsysproBNP II). The diagnosis of PAH is based on Dana point criteria at right heart catheterization (RHC). Patients with LV dysfunction or eGFR 36 mmHg, (ii) FVC/DLCO% >1.6 and no significant ILD, (iii) DLCO 189.2 pg/ml had a likelihood ratio of 26.4 for presence of PAH (c-statistic = 0.9; sensitivity 85%; specificity 97%). An NT-proBNP level 189.2 pg/ml and

Published
2017

38. Mapping and predicting mortality from systemic sclerosis

Author

Elhai, M. Meune, C. Boubaya, M. Avouac, J. Hachulla, E. Balbir-Gurman, A. Riemekasten, G. Airò, P. Joven, B. Vettori, S. Cozzi, F. Ullman, S. Czirják, L. Tikly, M. Müller-Ladner, U. Caramaschi, P. Distler, O. Iannone, F. Ananieva, L.P. Hesselstrand, R. Becvar, R. Gabrielli, A. Damjanov, N. Salvador, M.J. Riccieri, V. Mihai, C. Szücs, G. Walker, U.A. Hunzelmann, N. Martinovic, D. Smith, V. Müller, C.D.S. Montecucco, C.M. Opris, D. Ingegnoli, F. Vlachoyiannopoulos, P.G. Stamenkovic, B. Rosato, E. Heitmann, S. Distler, J.H.W. Zenone, T. Seidel, M. Vacca, A. Langhe, E.D. Novak, S. Cutolo, M. Mouthon, L. Henes, J. Chizzolini, C. Mühlen, C.A.V. Solanki, K. Rednic, S. Stamp, L. Anic, B. Santamaria, V.O. Santis, M.D. Yavuz, S. Sifuentes-Giraldo, W.A. Chatelus, E. Stork, J. Laar, J.V. Loyo, E. De La Peña Lefebvre, P.G. Eyerich, K. Cosentino, V. Alegre-Sancho, J.J. Kowal-Bielecka, O. Rey, G. Matucci-Cerinic, M. Allanore, Y.

Abstract

Objectives To determine the causes of death and risk factors in systemic sclerosis (SSc). Methods Between 2000 and 2011, we examined the death certificates of all French patients with SSc to determine causes of death. Then we examined causes of death and developed a score associated with all-cause mortality from the international European Scleroderma Trials and Research (EUSTAR) database. Candidate prognostic factors were tested by Cox proportional hazards regression model by single variable analysis, followed by a multiple variable model stratified by centres. The bootstrapping technique was used for internal validation. Results We identified 2719 French certificates of deaths related to SSc, mainly from cardiac (31%) and respiratory (18%) causes, and an increase in SSc-specific mortality over time. Over a median follow-up of 2.3 years, 1072 (9.6%) of 11 193 patients from the EUSTAR sample died, from cardiac disease in 27% and respiratory causes in 17%. By multiple variable analysis, a risk score was developed, which accurately predicted the 3-year mortality, with an area under the curve of 0.82. The 3-year survival of patients in the upper quartile was 53%, in contrast with 98% in the first quartile. Conclusion Combining two complementary and detailed databases enabled the collection of an unprecedented 3700 deaths, revealing the major contribution of the cardiopulmonary system to SSc mortality. We also developed a robust score to risk-stratify these patients and estimate their 3-year survival. With the emergence of new therapies, these important observations should help caregivers plan and refine the monitoring and management to prolong these patients' survival. ©Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Published
2017

39. THE GOOD PLACE AND TED SIDER'S PUZZLE.

Author

Joaquin, Jeremiah Joven B. and Biana, Hazel T.

Subjects
ATTRIBUTES of God, PUZZLES, TELEVISION programs, AFTERLIFE, CROSSWORD puzzles
Abstract

The hit American TV show The Good Place has garnered quite a following in recent years. Its main premise implies a scorekeeping view of the afterlife. People who have collected enough credits in their earthly lives will make the cut and go to the Good Place, while those who do not will be banished to the Bad Place. We suggest that such a premise would have to come to terms with Ted Sider's puzzle about the compatibility of a binary afterlife with God's divine attributes. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

40. Position statement for the management of comorbidities in psoriasis

Author

Dauden, E., primary, Blasco, A.J., additional, Bonanad, C., additional, Botella, R., additional, Carrascosa, J.M., additional, González-Parra, E., additional, Jodar, E., additional, Joven, B., additional, Lázaro, P., additional, Olveira, A., additional, Quintero, J., additional, and Rivera, R., additional

Published
2018
Full Text
View/download PDF

41. AB0625 Autoantibody profile in patients diagnosed with idiopathic inflammatory myopathy: multicenter registry on inflammatory myositis from the rheumatology society in madrid, spain

Author

Hernández Flόrez, DC, primary, Valor, L, additional, Martinez, J, additional, Joven, B, additional, Nuno, L, additional, Larena, C, additional, Llorente, I, additional, Barbadillo, C, additional, Pena, P Garcia de la, additional, Ruiz, L, additional, Moruno, H, additional, Cobo, T, additional, Almodovar, R, additional, Lojo, L, additional, Garcia, M, additional, and Lopez-Longo, F, additional

Published
2017
Full Text
View/download PDF

42. FRI0385 Joint manifestations in patients diagnosed with idiopathic inflammatory myopathy: multicenter registry

Author

Hernández Flόrez, DC, primary, Valor, L, additional, Martinez, J, additional, Joven, B, additional, Nuno, L, additional, Larena, C, additional, Llorente, I, additional, Barbadillo, C, additional, Pena, P Garcia de la, additional, Ruiz, L, additional, Moruno, H, additional, Cobo, T, additional, Almodovar, R, additional, Lojo, L, additional, Garcia, M, additional, and Lopez-Longo, F, additional

Published
2017
Full Text
View/download PDF

43. REPLICATION OF GWAS OF RESPONSE TO TNF INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS

Author

Ferreiro-Iglesias, A., Montes, A., Perez-Pampin, E., Carreira, P., Joven, B., Caliz, R., Ferrer, M.A., Moreno-Ramos, M.J., Raya, E., Magro, C., Vasilopoulos, Y., Sarafidou, T., Balsa, A., Pascual-Salcedo, D., Fernandez-Nebro, A., Ordonez, M.C., Alegre-Sancho, J.J., Marquez, A., Navarro, F., Moreira, V., Blanco, F.J., Narvaez, J., Canete, J.D., Martin, J., Gomez-Reino, J.J., and Gonzalez, A.

Published
2015

44. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors

Author

Montes, A, Perez-Pampin, E, Joven, B, Carreira, P, Fernandez-Nebro, A, Ordonez, MD, Navarro-Sarabia, F, Moreira, V, Vasilopoulos, Y, Sarafidou, T, Caliz, R, Ferrer, MA, Canete, JD, de la Serna, AR, Magallares, B, Narvaez, J, Gomez-Reino, JJ, and Gonzalez, A

Subjects
rheumatoid arthritis, TNF inhibitors, Fc receptor, adalimumab, biomarkers, biologics, genetics, FCGRT, infliximab, etanercept
Abstract

Objectives: Reproducible association of a functional polymorphism in FCGR2A with response to a TNF inhibitor (TNFi) in patients with rheumatoid arthritis (RA) led us to explore other Fc gamma R functional polymorphisms. Methods: Functional polymorphisms FCGR3A F158V, FCGR2B I223T and promoter VNTR in FCGRT were analyzed in up to 429 patients with RA. Response to TNFi was recorded during standard care at 3, 6 and 12 months of follow-up. Fixed effects meta-analysis of studies addressing FCGR3A F158V polymorphism, which is the most studied of these polymorphisms, was conducted with inverse variance weighting. Results: None of the functional polymorphisms were associated with change in DAS28. Meta-analysis of the seven studies (899 patients) with available data addressing association of FCGR3A F158V with response to TNFi in RA showed no association (OR: 1.11, 95% CI: 0.8-1.5; p = 0.5). Conclusion: None of the three functional polymorphisms in Fc gamma R genes showed association with response to TNFi in patients with RA. These negative results were obtained in spite of the larger size of this study relative to previous studies addressing the same polymorphisms. In addition, meta-analysis of FCGR3A F158V was also negative against the results provided by previous studies.

Published
2015

45. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database

Author

Walker U. A., Tyndall A., Czirják L, Denton C. ., Farge Bancel D., Kowal Bielecka O., Müller Ladner U., Bocelli Tyndall C., Matucci Cerinic M., Riemekasten G. ., Brückner C. ., Airó P. ., Scarsi M. ., Scorza R. ., Beretta L. ., Cozzi F. ., Tiso F., Vonk Mc M. C., Hoogen Van Den, Fhj F. H. J., Wigley Fm F. M., Hummers L. ., Nevskaya T. ., Ananieva L. ., Miniati I. ., Tartaglia N. ., Lomater C. ., Balbir Gurman A. ., Braun Moscovici Y. ., Bambara Lm L. M., Caramaschi P. ., Ruocco L. ., Krieg T. ., Hunzelmann N. ., Varjú C. ., Carriera Pe P. E., Joven B. ., Iannone F. ., Lapadula G. ., Kahan A. ., Allanore Y. ., Gabrielli A. ., Imperatore M. ., Scheja A. ., Wollheim F. ., Damjanov N. ., Ostojic P. ., Saar P. ., Tarner Ih I. H., Kötter I. ., Bombardieri S. ., Bazzichi L. ., Papa Del N. ., Comina Dp D. P., Monaco Lo A. ., Corte La R. ., Hachulla E. ., Launay D. ., Distler O. ., Ciurea A. ., Sierakowski S. ., Mitchell H. ., Silver Rm R. M., Krasowska D. ., Michalska Jakubus M. ., Tikly M. ., Aboo N. ., Worm M. ., Klaus P. ., Rovenský J. ., Lukáčová O. ., Rozman B. ., Sipek A. ., Clemente Coelho P. ., Shoenfeld Y. ., Langewitch P. ., José Da Silva Ap A. P., Salvador Mj M. J., Kuhn A. ., Erdmann G. ., Bečvář R. ., Friedl E. ., Graninger W. ., Riccieri V. ., Caporali R. ., Montecucco C. ., Vlachoyiannopoulos P. ., Distler M. ., Reich K. ., Majdan M. ., Wielosz E. ., Rednic S. ., Laar Van Jm J. M., Heitmann S. ., Bruckner A. ., Himsel A. ., Riemann J. ., Meyringer R. ., Müller A. ., Martinovic D. ., Radic M. ., Sticherling M. ., Szekanecz Z. ., Szücs G. ., Giacomelli R. ., Marrelli A. ., Stamenkovic B. ., Stankovic A. ., Aringer M. ., Smolen Js J. S., Kucharz Ej E. J., Kotulska At A. T., Jablonska S. ., Blasczik M. ., Jun J. B. J. B., Mallia C. ., Coleiro B. ., Santamaria Vo V. O., Hinrichs R. ., Nielsen H. ., Cossutta R. ., Ionescu R. ., Opris D. ., Steinbrink K. ., Grundt B. ., Bajocchi G. ., Jiří Š. ., Lefebvre Pgdlp P. G. D. L. P., Mendoza ZeaAc A. C., Ribi C. ., Chizzolini C. ., Wisłowska M. ., Novak S. ., Indiveri F. ., Jacobsen S. ., Frandsen Pb P. B., Gorska Iz I. Z., Gran Tore J. ., Midtvedt Ø. ., Ramos Fo F. O., Rajcevska Ld L. D., Bozinovski G. ., Schöffel D. ., Sunderkötter C. ., Böhm M. ., Morović Vergles J. ., Čulo M. I. M. I., Cutolo M. ., Sulli A. ., Derk Ct C. T., Jimenez Sa S. A., Siakka P. ., Søndergaard K. ., Stengaard Pedersen K. ., Cabane J. ., Tiev Kp K. P., Mihai C. ., Sfrent Cornateanu R. ., Jendro M. ., Tuvik P. ., Antivalle M. ., Randisi G. ., Seidel M. ., Clarenbach R. ., Simsek I. ., Dinc A. ., Inanc M. ., Capraru Ms M. S., Capraru D. ., Bañegil I. ., Richter J. ., Alhasani S. ., Földvari I. ., Pinto S. ., Brandão F. ., VALENTINI, Gabriele, Walker, U. A., Tyndall, A., Czirják, L, Denton, C. ., Farge Bancel, D., Kowal Bielecka, O., Müller Ladner, U., Bocelli Tyndall, C., Matucci Cerinic, M., Riemekasten, G. ., Brückner, C. ., Airó, P. ., Scarsi, M. ., Scorza, R. ., Beretta, L. ., Cozzi, F. ., Tiso, F., Vonk Mc, M. C., Hoogen Van, Den, Fhj, F. H. J., Wigley Fm, F. M., Hummers, L. ., Nevskaya, T. ., Ananieva, L. ., Miniati, I. ., Tartaglia, N. ., Lomater, C. ., Balbir Gurman, A. ., Braun Moscovici, Y. ., Bambara Lm, L. M., Caramaschi, P. ., Valentini, Gabriele, Ruocco, L. ., Krieg, T. ., Hunzelmann, N. ., Varjú, C. ., Carriera Pe, P. E., Joven, B. ., Iannone, F. ., Lapadula, G. ., Kahan, A. ., Allanore, Y. ., Gabrielli, A. ., Imperatore, M. ., Scheja, A. ., Wollheim, F. ., Damjanov, N. ., Ostojic, P. ., Saar, P. ., Tarner Ih, I. H., Kötter, I. ., Bombardieri, S. ., Bazzichi, L. ., Papa Del, N. ., Comina Dp, D. P., Monaco Lo, A. ., Corte La, R. ., Hachulla, E. ., Launay, D. ., Distler, O. ., Ciurea, A. ., Sierakowski, S. ., Mitchell, H. ., Silver Rm, R. M., Krasowska, D. ., Michalska Jakubus, M. ., Tikly, M. ., Aboo, N. ., Worm, M. ., Klaus, P. ., Rovenský, J. ., Lukáčová, O. ., Rozman, B. ., Sipek, A. ., Clemente Coelho, P. ., Shoenfeld, Y. ., Langewitch, P. ., José Da Silva Ap, A. P., Salvador Mj, M. J., Kuhn, A. ., Erdmann, G. ., Bečvář, R. ., Friedl, E. ., Graninger, W. ., Riccieri, V. ., Caporali, R. ., Montecucco, C. ., Vlachoyiannopoulos, P. ., Distler, M. ., Reich, K. ., Majdan, M. ., Wielosz, E. ., Rednic, S. ., Laar Van Jm, J. M., Heitmann, S. ., Bruckner, A. ., Himsel, A. ., Riemann, J. ., Meyringer, R. ., Müller, A. ., Martinovic, D. ., Radic, M. ., Sticherling, M. ., Szekanecz, Z. ., Szücs, G. ., Giacomelli, R. ., Marrelli, A. ., Stamenkovic, B. ., Stankovic, A. ., Aringer, M. ., Smolen Js, J. S., Kucharz Ej, E. J., Kotulska At, A. T., Jablonska, S. ., Blasczik, M. ., Jun, J. B. J. B., Mallia, C. ., Coleiro, B. ., Santamaria Vo, V. O., Hinrichs, R. ., Nielsen, H. ., Cossutta, R. ., Ionescu, R. ., Opris, D. ., Steinbrink, K. ., Grundt, B. ., Bajocchi, G. ., Jiří, Š. ., Lefebvre Pgdlp, P. G. D. L. P., Mendoza ZeaAc, A. C., Ribi, C. ., Chizzolini, C. ., Wisłowska, M. ., Novak, S. ., Indiveri, F. ., Jacobsen, S. ., Frandsen Pb, P. B., Gorska Iz, I. Z., Gran Tore, J. ., Midtvedt, Ø. ., Ramos Fo, F. O., Rajcevska Ld, L. D., Bozinovski, G. ., Schöffel, D. ., Sunderkötter, C. ., Böhm, M. ., Morović Vergles, J. ., Čulo, M. I. M. I., Cutolo, M. ., Sulli, A. ., Derk Ct, C. T., Jimenez Sa, S. A., Siakka, P. ., Søndergaard, K. ., Stengaard Pedersen, K. ., Cabane, J. ., Tiev Kp, K. P., Mihai, C. ., Sfrent Cornateanu, R. ., Jendro, M. ., Tuvik, P. ., Antivalle, M. ., Randisi, G. ., Seidel, M. ., Clarenbach, R. ., Simsek, I. ., Dinc, A. ., Inanc, M. ., Capraru Ms, M. S., Capraru, D. ., Bañegil, I. ., Richter, J. ., Alhasani, S. ., Földvari, I. ., Pinto, S. ., Brandão, F. ., Ribi, Camillo, and Chizzolini, Carlo

Subjects
Male, Systemic disease, Databases, Factual, Cross-sectional study, Scleroderma, Immunopathology, Immunology and Allergy, Age of Onset, skin and connective tissue diseases, ddc:616, integumentary system, Nuclear Proteins, Orvostudományok, Middle Aged, Connective tissue disease, Extended Report, Raynaud Disease/etiology/immunology, DNA Topoisomerases, Type I, Nuclear Proteins/immunology, Female, Adult, medicine.medical_specialty, Scleroderma, Diffuse/complications/immunology, Immunology, Klinikai orvostudományok, Scleroderma, Systemic/complications/immunology, Risk Assessment, General Biochemistry, Genetics and Molecular Biology, systemic sclerosis, EULAR, risk assessment, Age Distribution, Sex Factors, Rheumatology, Scleroderma, Limited, medicine, Humans, Risk factor, Aged, Autoantibodies, Scleroderma, Systemic, business.industry, Autoantibody, Raynaud Disease, medicine.disease, Dermatology, Cross-Sectional Studies, Scleroderma, Diffuse, Scleroderma, Limited/complications/immunology, Age of onset, business, Autoantibodies/blood
Abstract

Background: Systemic sclerosis (SSc) is a multisystem autoimmune disease which is classified into a diffuse cutaneous (dcSSc) and a limited cutaneous (lcSSc) subset according to the skin involvement. In order to better understand the vascular, immunological and fibrotic processes of SSc and to guide its treatment the EULAR Scleroderma Trials And Research (EUSTAR) group was formed in June 2004. Aims and Methods: EUSTAR collects prospectively the Minimal Essential Data Set (MEDS) on all sequential patients fulfilling the ACR diagnostic criteria in participating centres. We aimed to characterize demographic, clinical and laboratory characteristics of disease presentation in SSc and analysed EUSTAR baseline visits. Results: In April 2006, a total of 3656 patients (1349 with dcSSc and 2101 with lcSSc) were enrolled in 102 centres and 30 countries. 1330 individuals had autoantibodies against Scl70 and 1106 against anticentromere antibodies. 87% of patients were female. On multivariate analysis, scleroderma subsets (dcSSc vs. lcSSc), antibody status and age at onset of Raynaud’s phenomenon, but not gender were independently associated with the prevalence of organ manifestations. Autoantibody status in this analysis appeared more closely associated with clinical manifestations than were SSc subsets. Conclusion: dcSSc and lcSSc subsets are associated with particular organ manifestations, but in this analysis the clinical distinction appeared superseded by an antibody based classification in predicting some scleroderma complications. The EUSTAR MEDS data base facilitates the analysis of clinical patterns in SSc and contributes to the standardised assessment and monitoring of SSc internationally.

Published
2007

46. OP0125 Replication of GWAS of Response to TNF Inhibitors in Patients with Rheumatoid Arthritis

Author

Ferreiro-Iglesias, A., primary, Montes, A., additional, Pérez-Pampín, E., additional, Carreira, P., additional, Joven, B., additional, Caliz, R., additional, Ferrer, M.A., additional, Moreno-Ramos, M.J., additional, Raya, E., additional, Magro, C., additional, Vasilopoulos, Y., additional, Sarafidou, T., additional, Balsa, A., additional, Pascual-Salcedo, D., additional, Fernández-Nebro, A., additional, Ordόñez, M.C., additional, Alegre-Sancho, J.J., additional, Márquez, A., additional, Navarro, F., additional, Moreira, V., additional, Blanco, F.J., additional, Narvaez, J., additional, Cañete, J.D., additional, Martin, J., additional, Gόmez-Reino, J.J., additional, and Gonzalez, A., additional

Published
2015
Full Text
View/download PDF

48. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis

Author

Ferreiro-Iglesias, A, primary, Montes, A, additional, Perez-Pampin, E, additional, Cañete, J D, additional, Raya, E, additional, Magro-Checa, C, additional, Vasilopoulos, Y, additional, Sarafidou, T, additional, Caliz, R, additional, Ferrer, M A, additional, Joven, B, additional, Carreira, P, additional, Balsa, A, additional, Pascual-Salcedo, D, additional, Blanco, F J, additional, Moreno-Ramos, M J, additional, Fernández-Nebro, A, additional, Ordóñez, M C, additional, Alegre-Sancho, J J, additional, Narváez, J, additional, Navarro-Sarabia, F, additional, Moreira, V, additional, Valor, L, additional, García-Portales, R, additional, Marquez, A, additional, Martin, J, additional, Gómez-Reino, J J, additional, and Gonzalez, A, additional

Published
2015
Full Text
View/download PDF

49. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group database

Author

Walker, U.A. Tyndall, A. Czirják, L. Denton, C. Farge-Bancel, D. Kowal-Bielecka, O. Müller-Ladner, U. Bocelli-Tyndall, C. Matucci-Cerinic, M. Riemekasten, G. Brückner, C. Airó, P. Scarsi, M. Scorza, R. Beretta, L. Cozzi, F. Tiso, F. Vonk, M.C. Van Den Hoogen, F.H.J. Wigley, F.M. Hummers, L. Nevskaya, T. Ananieva, L. Miniati, I. Tartaglia, N. Lomater, C. Balbir-Gurman, A. Braun-Moscovici, Y. Bambara, L.M. Caramaschi, P. Valentini, G. Ruocco, L. Krieg, T. Hunzelmann, N. Varjú, C. Carriera, P.E. Joven, B. Iannone, F. Lapadula, G. Kahan, A. Allanore, Y. Gabrielli, A. Imperatore, M. Scheja, A. Wollheim, F. Damjanov, N. Ostojic, P. Saar, P. Tarner, I.H. Kötter, I. Bombardieri, S. Bazzichi, L. Del Papa, N. Comina, D.P. Lo Monaco, A. La Corte, R. Hachulla, E. Launay, D. Distler, O. Ciurea, A. Sierakowski, S. Mitchell, H. Silver, R.M. Krasowska, D. Michalska-Jakubus, M. Tikly, M. Aboo, N. Worm, M. Klaus, P. Rovenský, J. Lukáčová, O. Rozman, B. Sipek, A. Clemente-Coelho, P. Shoenfeld, Y. Langewitch, P. Da Silva José, A.P. Salvador, M.J. Kuhn, A. Erdmann, G. Bečvář, R. Friedl, E. Graninger, W. Riccieri, V. Caporali, R. Montecucco, C. Vlachoyiannopoulos, P. Distler, M. Reich, K. Majdan, M. Wielosz, E. Rednic, S. Van Laar, J.M. Heitmann, S. Bruckner, A. Himsel, A. Riemann, J. Meyringer, R. Müller, A. Martinovic, D. Radic, M. Sticherling, M. Szekanecz, Z. Szücs, G. Giacomelli, R. Marrelli, A. Stamenkovic, B. Stankovic, A. Aringer, M. Smolen, J.S. Kucharz, E.J. Kotulska, A.T. Jablonska, S. Blasczik, M. Jun, J.-B. Mallia, C. Coleiro, B. Santamaria, V.O. Hinrichs, R. Nielsen, H. Cossutta, R. Ionescu, R. Opris, D. Steinbrink, K. Grundt, B. Bajocchi, G. Jiří, Š. Lefebvre, P.G.D.L.P. Zea Mendoza, A.C. Ribi, C. Chizzolini, C. Wisłowska, M. Novak, S. Indiveri, F. Jacobsen, S. Frandsen, P.B. Gorska, I.Z. Tore Gran, J. Midtvedt, Ø. Ramos, F.O. Rajcevska, L.D. Bozinovski, G. Schöffel, D. Sunderkötter, C. Böhm, M. Morović-Vergles, J. Čulo, M.-I. Cutolo, M. Sulli, A. Derk, C.T. Jimenez, S.A. Siakka, P. Søndergaard, K. Stengaard-Pedersen, K. Cabane, J. Tiev, K.P. Mihai, C. Sfrent-Cornateanu, R. Jendro, M. Tuvik, P. Antivalle, M. Randisi, G. Seidel, M. Clarenbach, R. Simsek, I. Dinc, A. Inanc, M. Capraru, M.S. Capraru, D. Bañegil, I. Richter, J. Alhasani, S. Földvari, I. Pinto, S. Brandão, F. Mas, A.J.

Subjects
integumentary system, skin and connective tissue diseases
Abstract

Background: Systemic sclerosis (SSc) is a multisystem autoimmune disease, which is classified into a diffuse cutaneous (dcSSc) and a limited cutaneous (IcSSc) subset according to the skin involvement. In order to better understand the vascular, immunological and fibrotic processes of SSc and to guide its treatment, the EULAR Scleroderma Trials And Research (EUSTAR) group was formed in June 2004. Aims and methods: EUSTAR collects prospectively the Minimal Essential Data Set (MEDS) on all sequential patients fulfilling the American College of Rheumatology diagnostic criteria in participating centres. We aimed to characterise demographic, clinical and laboratory characteristics of disease presentation in SSc and analysed EUSTAR baseline visits. Results: In April 2006, a total of 3656 patients (1349 with dcSSc and 2101 with IcSSc) were enrolled in 102 centres and 30 countries. 1330 individuals had autoantibodies against Scl70 and 1106 against anticentromere antibodies. 87% of patients were women. On multivariate analysis, scleroderma subsets (dcSSc vs IcSSc), antibody status and age at onset of Raynaud's phenomenon, but not gender, were found to be independently associated with the prevalence of organ manifestations. Autoantibody status in this analysis was more closely associated with clinical manifestations than were SSc subsets. Conclusion: dcSSc and IcSSc subsets are associated with particular organ manifestations, but in this analysis the clinical distinction seemed to be superseded by an antibody-based classification in predicting some scleroderma complications. The EUSTAR MEDS database facilitates the analysis of clinical patterns in SSc, and contributes to the standardised assessment and monitoring of SSc internationally.

Published
2007

50. An Alternative Dialectical Picture of the Phenomenal Concept Strategy Debate: A Reply to Mabaquiao.

Author

Joaquin, Jeremiah Joven B.

Subjects
PHENOMENALISM, EPISTEMIC logic, SOCIOLOGY of knowledge, DEBATE, ONTOLOGICAL proof of God
Abstract

In "Phenomenal Concept Strategy and a Master Argument," Mabaquiao presents the debate between physicalists and anti-physicalists in light of the plausibility of the phenomenal concept strategy vis-à-vis Chalmers' master argument. He argues that, as it currently stands, the debate is at an ontological stalemate. This paper argues that this indictment is not fair given an alternative picture of the current dialectical status of the debate. Furthermore, it suggests that, given this picture, we could have reasons to favor the anti-physicalists over the physicalists just by following how the debate has currently been pursued. [ABSTRACT FROM AUTHOR]

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results